15 May 2017 in The Journal of Immunology
Histone acetyltransferases (HATs) regulate inducible transcription in multiple cellular processes and during inflammatory and immune response. However, the functions of general control nonrepressed–protein 5 (Gcn5), an evolutionarily conserved HAT from yeast to human, in immune regulation remain unappreciated. In this study, we conditionally deleted Gcn5 (encoded by the Kat2a gene) specifically in T lymphocytes by crossing floxed Gcn5 and Lck-Cre mice, and demonstrated that Gcn5 plays important roles in multiple stages of T cell functions including development, clonal expansion, and differentiation. Loss of Gcn5 functions impaired T cell proliferation, IL-2 production, and Th1/Th17, but not Th2 and regulatory T cell differentiation. Gcn5 is recruited onto the il-2 promoter by interacting with the NFAT in T cells upon TCR stimulation. Interestingly, instead of directly acetylating NFAT, Gcn5 catalyzes histone H3 lysine H9 acetylation to promote IL-2 production. T cell–specific suppression of Gcn5 partially protected mice from myelin oligodendrocyte glycoprotein–induced experimental autoimmune encephalomyelitis, an experimental model for human multiple sclerosis. Our study reveals previously unknown physiological functions for Gcn5 and a molecular mechanism underlying these functions in regulating T cell immunity. Hence Gcn5 may be an important new target for autoimmune disease therapy.
26 March 2025 in Journal of Chemical Information and Modeling
14 January 2025 in Advanced Intelligent Systems
Immunotherapy has revolutionized cancer treatment, but predicting patient response remains challenging. Herein, we present iPRISM (Intelligent Predicting Response to cancer Immunotherapy through Systematic Modeling), which is a novel network‐based model that integrates multiomics data to predict immunotherapy outcomes. In this approach, iPRISM incorporates gene expression, biological functional network, tumor microenvironment characteristics, immune‐related pathways, and clinical data to provide a comprehensive view of factors influencing immunotherapy efficacy. Using stepwise logistic regression, we identified key predictive features and validated iPRISM across multiple cohorts including melanoma, bladder cancer, non‐small cell lung cancer, and stomach adenocarcinoma. We also find that iPRISM outperforms the existing methods, achieving high predictive accuracy and demonstrating significant prognostic value for overall and progression‐free survival. By identifying key genetic and immunological factors, this model provides a new insight for more personalized treatment strategies and combination therapies to overcome resistance mechanisms. iPRISM can be accessed at CRAN: https://CRAN.R‐project.org/package=iPRISM.